1. Home
  2. PLCE vs SAVA Comparison

PLCE vs SAVA Comparison

Compare PLCE & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Children's Place Inc. (The)

PLCE

Children's Place Inc. (The)

N/A

Current Price

$3.69

Market Cap

100.2M

ML Signal

N/A

Logo Cassava Sciences Inc.

SAVA

Cassava Sciences Inc.

HOLD

Current Price

$2.37

Market Cap

96.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLCE
SAVA
Founded
1969
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.2M
96.1M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
PLCE
SAVA
Price
$3.69
$2.37
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
$4.50
$5.00
AVG Volume (30 Days)
242.7K
640.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
63.35
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.65
$1.15
52 Week High
$9.56
$4.98

Technical Indicators

Market Signals
Indicator
PLCE
SAVA
Relative Strength Index (RSI) 34.43 57.06
Support Level N/A $1.94
Resistance Level $4.79 $2.51
Average True Range (ATR) 0.20 0.14
MACD -0.01 0.00
Stochastic Oscillator 5.53 73.58

Price Performance

Historical Comparison
PLCE
SAVA

About PLCE Children's Place Inc. (The)

Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Share on Social Networks: